Citius Pharmaceuticals, Inc.
CTXR
$0.77
-$0.06-6.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.56% | -2.39% | 5.18% | 19.75% | 26.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.26% | -8.26% | 0.17% | 9.91% | 9.97% |
| Operating Income | 13.50% | 8.26% | -0.17% | -9.91% | -9.97% |
| Income Before Tax | 4.99% | 0.43% | -9.07% | -19.66% | -5.78% |
| Income Tax Expenses | 51.80% | 83.47% | 62.60% | 41.74% | 20.87% |
| Earnings from Continuing Operations | 4.01% | -0.80% | -9.87% | -20.01% | -6.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 270.81% | 703.62% | -- | -- | -- |
| Net Income | 9.55% | 4.36% | -5.15% | -16.16% | -3.92% |
| EBIT | 13.50% | 8.26% | -0.17% | -9.91% | -9.97% |
| EBITDA | 14.84% | 8.26% | -0.17% | -9.92% | -9.98% |
| EPS Basic | 49.77% | 35.54% | 18.67% | 3.11% | 8.94% |
| Normalized Basic EPS | 54.31% | 40.73% | 24.96% | 10.74% | 3.77% |
| EPS Diluted | 49.77% | 35.54% | 19.27% | 5.76% | 11.26% |
| Normalized Diluted EPS | 54.31% | 40.73% | 24.96% | 10.74% | 3.77% |
| Average Basic Shares Outstanding | 107.83% | 64.55% | 31.81% | 19.95% | 13.46% |
| Average Diluted Shares Outstanding | 107.83% | 64.55% | 31.81% | 19.95% | 13.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |